Electroceuticals: Microcurrents as medicine
Bioelectric medicine was born 60 years ago with the pacemaker. Using electro-technologies to modify bodily functions grew slowly and steadily after that … from pacemakers in 1958, to spinal cord stimulation (SCS) in 1967, to inner ear implants in 1978… bioelectric medicine has come a long way towards extending the lives of patients.
Discoveries like those were so sporadic and treated so many different symptoms that most people didn’t realize they were connected… yet they’re all bioelectronics, also called electro-medicine.
With advances in micro processing this field is suddenly exploding, and yesterday’s slow-and-seldom breakthroughs have turned into a tsunami of rapid discoveries and new treatments. These new treatments are so much more flexible and powerful that they’ve caught the attention of a number of major corporations who are developing electroceutical devices of their own.
This Technology Just Spawned a New Medical Sector with a Fast Growing $35 Billion Market
Grandview Research predicts that electroceutical/bioelectric medicine will be a $35.5 billion market by 2025. Many forward-thinking investors have already taken positions in bioelectric medicine, as the field is still young and has enormous growth potential. Another sign that bioelectric medicine is on firm footing is the number of major corporations that are entering the sector, below are examples of 4 corporations making strides in bioelectric medicine.
GlaxoSmithKline (GSK), with support from Alphabet, set up Galvani Bioelectronics to work on an implant device that will wrap around a bundle of nerves to treat diseases.
Boston Scientific (BSX) & Medtronic (MDX) – Both companies have a long history in bioelectronics with pacemakers and spinal cord stimulation devices.
Nevro Corp. (NVRO) – Makes pain control devices using spinal cord stimulation (SCS).
The common theme with the above examples is that their procedures are all invasive in nature. Standing out amongst these large corporations is a small company by the name of Cell MedX who has just completed observational clinical trials for their eBalance device.
Cell MedX Corp. (CMXC) – Is a pure-play electroceutical that has just completed observational clinical trials for its eBalance device.
Unique Opportunity in a Pure Electroceuticals Play
The very nature of Cell MedX’s eBalance device is very different from other microcurrent systems. Instead of stimulating the spinal cord or muscles or providing other localized application of electrical stimulation, eBalance instead delivers microcurrents in various strengths, frequencies and waveforms through the body in 15 to 30 minute treatments.
Observational Clinical Trial Results as Reported by the Company
An observational clinical trial was completed on diabetic subjects using 3 months of eBalance treatments twice weekly (the “Trial”) with no significant side effects or safety issues. The following results were observed during the Trial;
After three months of bi-weekly eBalance treatments, the average fasting blood glucose levels declined by 12.3% and plasma insulin declined by 46.7%. These results indicate that, on average, the blood glucose uptake was increased and that less insulin was required to achieve that uptake. A longer double-blind, placebo controlled study may be conducted in the future to determine if grater effects are achieved as seen in individuals who have used the device over extended periods of time.
After 7 weeks of treatments, systolic pressure, the higher amount of pressure in the arteries during the contraction of the heart muscle, declined by 9.6% and diastolic pressure, the lower pressure number in the arteries when the heart muscle is between beats, declined by 10.4%. The Company is planning to undertake further studies on subjects with higher blood pressures to determine if a proportional effect is obtained as has been observed with in individuals who have used the eBalanceTM device. A 10% decrease in blood pressure for individuals at risk from high blood pressure could be very beneficial without the side effects of medications.
Pain and numbness
Neuropathy is nerve damage that can occur with diabetes as a result of high blood glucose levels and high blood pressure. The damage most often affects the extremities and causes pain, tingling or numbness in the hands, arms, legs and feet. Only two subjects suffered from pain at the beginning of the Trial and both reported feeling either less pain or reduced coldness or numbness in their extremities. These findings support our individual findings and he Company is wanting to conduct further studies on neuropathy and other forms of chronic pain, such as gout, migraines and inflammation.
Nephropathy is damage caused to the small blood vessels in the kidneys by high blood glucose levels and high blood pressure that prevents them from functioning properly or even causes them to fail completely. When the blood vessels in the kidneys are injured, the kidneys cannot clean the blood properly. The body will retain more water and salt than it should, which can result in weight gain and edema. In the Trial, there were some indications that eBalance treatments improved kidney function which is supported by individual observations of significant reductions of edema. A longer study on studies on kidney function is highly desirable.
Cell MedX Corp. (CMXC), a fully-reporting US-listed company and a reporting issuer in Canada
Investing in Cell MedX (CMXC)
Unique Electroceutical Opportunity—CellMedX offers a pure play on the fast-evolving field of electroceuticals.
Millions of Potential Users—Having completed observational trials to demonstrate the efficacy for diabetes, blood sugar and blood pressure treatment, CellMedX is targeting the
global population of 380 million diabetics and 1.1 Billion people suffering from high blood pressure.
Meaningful Innovation—The eBalance device may prove to be an important breakthrough in diabetes management.
Outstanding safety—Even insulin therapy can be dangerous for diabetics, but the eBalance microcurrent treatments through its observational clinical trials has demonstrated no harmful side effects.
Easy to use— eBalance incorporates a user-friendly interface.
Pipeline Potential —Outstanding potential for follow-on devices built with the same technology to address other health problems.
Global Ambition— Cell MedX (CMXC) is taking the necessary steps to gain approval in the US, EU, and Commonwealth countries.
- In 2016, 415 million adults will have diabetes.
Expected to rise to 642 million worldwide by 2040.
Currently 316 million people at high risk of developing type II diabetes.
Expected to be nearly 600 million pre-diabetics within 20 years.
In 2010, 43,800 people in the US had lower limb amputations resulting from diabetic neuropathy.
In 2011, 50,000 people began treatment for kidney failure due to diabetes.
Global expenditure to combat diabetes is $673 billion per year.
12% of global expenditures on healthcare.
US total medical costs for diabetes is $245 billion per year and rising.
Continue reading about the eBalance Solution
- Publicly listed: OTCQB: CMXC
CUSIP Number: 15115X 107
ISIN Number: US15115X1072
State of Incorporation: NV
Date of Incorporation: March 19, 2010
SEC Reporting Status: Compliant
Fiscal Year End: May 31
Shares Issued and Outstanding: 40,244,605 as of October 17, 2016
View Share Trading Data
Review Regulatory Filings
Read Our Corporate News
Contact Investor Relations
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.